Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2436-46. doi: 10.1007/s00259-010-1545-7.
The aim of this document is to provide general information about mIBG scintigraphy in cancer patients. The guidelines describe the mIBG scintigraphy protocol currently used in clinical routine, but do not include all existing procedures for neuroendocrine tumours. The guidelines should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary from one country to another and from one medical institution to another. The present guidelines have been prepared for nuclear medicine physicians and intend to offer assistance in optimizing the diagnostic information that can currently be obtained from mIBG scintigraphy. The corresponding guidelines of the Society of Nuclear Medicine (SNM) and the Dosimetry, Therapy and Paediatric Committee of the EANM have been taken into consideration, and partially integrated into this text. The same has been done with the most relevant literature on this topic, and the final result has been discussed within a group of distinguished experts.
本文件的目的是提供有关癌症患者间碘苄胍闪烁扫描的一般信息。本指南描述了目前在临床常规中使用的 mIBG 闪烁扫描方案,但不包括所有用于神经内分泌肿瘤的现有程序。因此,这些指南不应被视为排除其他可用于获得可比结果的核医学方式。重要的是要记住,患者护理的可用资源和设施可能因国家和医疗机构而异。本指南是为核医学医师编写的,旨在帮助优化目前可从 mIBG 闪烁扫描中获得的诊断信息。已考虑到核医学学会 (SNM) 和欧洲核医学协会剂量学、治疗和儿科委员会的相应指南,并将其部分纳入本文本。同样,也考虑了关于这个主题的最相关的文献,最终结果在一组杰出的专家中进行了讨论。